Related Experiment Videos
Safety of intravenous diazoxide in children with severe hypertension
Insights
Intravenous diazoxide effectively and safely lowers blood pressure in children with acute severe hypertension. Repeated use is also safe and effective for recurrent hypertension episodes.
Area of Science:
- Pediatric Nephrology
- Clinical Pharmacology
Background:
- Acute severe hypertension in children requires prompt and effective treatment.
- Intravenous medications are often necessary for rapid blood pressure reduction in pediatric emergencies.
Purpose of the Study:
- To evaluate the safety and efficacy of intravenous diazoxide in treating acute severe hypertension in children.
- To assess the drug's effectiveness in both initial and recurrent hypertensive episodes.
Main Methods:
- A collaborative study observed 36 pediatric patients (2 months to 18 years) with acute severe hypertension.
- Blood pressure response and adverse effects were monitored during intravenous diazoxide administration.
Main Results:
- Intravenous diazoxide effectively lowered blood pressure in 94% of initial treatment cases.
- No serious adverse circulatory, fluid/electrolyte, metabolic, or hematologic effects were noted.
- Repeated diazoxide administration for recurrent hypertension was effective and safe in 93% of instances.
Conclusions:
- Intravenous diazoxide is a safe and effective treatment for acute severe hypertension in children.
- It is particularly recommended for pediatric hypertension refractory to other agents.
- Other antihypertensive therapies can be safely reinstituted after the transient hypotensive effect subsides.
Abstract:
The safety and efficacy of diazoxide administered intravenously in the treatment of children with acute severe hypertension have been evaluated by a collaborative study. Observations of the response of blood pressure in 36 patients, ranging in age from two months to 18 years, during the initial episode of hospitalization reveal diazoxide treatment to be effective in lowering blood pressure in 94 per cent of the cases. No serious adverse circulatory, fluid and electrolyte, metabolic or hematologic effects were observed. Symptomatic and subjective reactions observed with diazoxide administered intravenously to children were identical with those described in adults. Reinstitution of other means of antihypertensive therapy is safe and effective when delayed until the transiently induced period of hypotension has passed. Repeated use of diazoxide for subsequent recurrence of severe hypertension was equally effective and safe in 93 per cent of the instances. The results lead us to recommend the use of intravenous diazoxide for treatment of children with severe symptomatic hypertension especially when it is refractory to control by other hypertensive agents.